A recent study indicates that tirzepatide, a treatment for obesity, may enhance metabolism by activating brown adipose tissue in obese mice. This finding could lead to new insights into the drug's effects beyond appetite suppression, potentially informing future obesity treatmen…
Access to obesity drugs in the UK is divided between a slow NHS rollout of tirzepatide and a rapidly growing private market. The NHS aims to provide access over 12 years, starting…
A new Scientific Statement from the Endocrine Society underscores the importance of focusing on health improvements rather than solely on weight loss in obesity treatment. The sta…
As GLP-1 medications gain popularity for weight loss, their use among college women during sorority recruitment raises concerns about body image pressures. A recent analysis indic…
In a conversation with integrative medicine physician Keshav Grover, the complexities of wellness trends, particularly peptides, are examined. Grover emphasizes a minimalist appro…
A recent study utilized AI to analyze over 400,000 Reddit posts discussing GLP-1 medications, revealing side effects like fatigue and reproductive changes that are often overlooke…
A recent analysis reveals that prescription rates for GLP-1 weight-loss medications, such as Wegovy and Mounjaro, are significantly lower in England's most deprived areas, despite…
A recent review in JAMA Otolaryngology highlights the potential benefits of GLP-1 weight-loss drugs, such as tirzepatide, in reducing the severity of obesity-related sleep apnea.…
The article highlights the historical separation between the fields of eating disorders and obesity, emphasizing the need for a collaborative approach to improve patient assessmen…
As GLP-1 medications gain popularity for weight loss, many users face the dilemma of whether they can stop the injections without regaining weight. Experts highlight the risks ass…
The FDA has granted approval for Mounjaro (tirzepatide) to reduce cardiovascular risk in individuals with type 2 diabetes, marking a significant development in diabetes management…
As metabolic health gains prominence in wellness discussions, the roles of NAD+ and GLP-1 therapies are increasingly scrutinized. This article clarifies how GLP-1 medications like…
Apnimed is preparing for a $160 million initial public offering on the Nasdaq to support the development of its lead therapy for obstructive sleep apnoea (OSA). The Massachusetts-…
As international drug companies ramp up their demands for higher prices, Australia faces a looming crisis in access to essential medications, leading to a farcical standoff that p…